VOR
Vor Biopharma Inc.
Company Overview
| Mkt Cap | $212.95M | Price | $14.53 |
| Volume | 850.48K | Change | +7.39% |
| P/E Ratio | -1.8 | Open | $13.50 |
| Revenue | -- | Prev Close | $13.53 |
| Net Income | $-116.9M | 52W Range | $2.62 - $65.80 |
| Div Yield | N/A | Target | $40.60 |
| Overall | 48 | Value | 60 |
| Quality | -- | Technical | 36 |
No chart data available
About Vor Biopharma Inc.
Vor Biopharma Inc. operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies. The company is also developing Mylotarg, a CD33-directed antibody drug conjugate (ADC) therapy for patients with leukemia; VCAR33, a CAR-T therapy designed to target CD33, a clinically validated target for AML, which are under preclinical and Phase 1/2 clinical studies; trem-cel + VCAR33 treatment system that is under preclinical studies for the treatment of AML; and CD33-CLL1 treatment system made with CD33-CLL1 multiplex-engineered eHSC and CD33-CLL1 multi-specific CAR-T, which are under preclinical studies for the treatment of AML. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Latest News
Vor Biopharma (VOR) Gets a Buy from TD Cowen
Vor Biopharma Approves Stock Option Repricing Plan
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | VOR | $14.53 | +7.4% | 850.48K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |